Envoy Medical, Inc. filed a Form 8-K on October 27, 2026, disclosing that a 1-for-10 reverse stock split of its Class A common stock became effective on October 26, 2026, at 12:01 a.m. Eastern Time.

Key Highlights

  • Reverse stock split ratio: 1-for-10, meaning every 10 issued and outstanding shares of Class A common stock were automatically combined into one share.
  • Effective date: October 26, 2026, at 12:01 a.m. Eastern Time; post-split trading on The Nasdaq Capital Market began at the open of trading that same day.
  • Stockholder approval: The Company's stockholders approved the amendment at a special meeting held on October 12, 2026, authorizing the board to set a ratio between 1-for-5 and 1-for-25.
  • Board determination: On October 12, 2026, following the special meeting, the board determined to effect the split at the 1-for-10 ratio.
  • Ticker and CUSIP: The ticker symbol remains "COCH" on Nasdaq; the post-split CUSIP number is 29415V307.
  • Fractional shares: No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment in lieu thereof.
  • Transfer agent: Equiniti will act as exchange agent and will provide stockholders with a transaction statement reflecting post-split shareholdings.

Envoy Medical's 1-for-10 Reverse Split: Certificate Filed, Trading Adjusted

According to the filing, Envoy Medical, Inc. (NASDAQ:COCH) filed a certificate of amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on October 23, 2026. The amendment effectuated the 1-for-10 reverse stock split of the Company's Class A common stock, which the filing states became effective on October 26, 2026, at 12:01 a.m. Eastern Time. As of that date, the Company's common stock began trading on a post-split basis on The Nasdaq Capital Market.

The Company disclosed that the par value and other terms of the common stock are not affected by the reverse stock split. In addition, the filing states that the exercise prices of, and the number of shares subject to, outstanding warrants and other convertible securities will be proportionately adjusted in accordance with their respective terms. The administrator of each of the Company's existing stock incentive and compensation plans will also make equitable adjustments required or permitted under the applicable plan, reflecting the 1-for-10 ratio, including adjustments to outstanding options, stock appreciation rights, restricted stock units, performance-based restricted stock units, restricted stock, other stock-based awards, and outstanding purchase rights, as well as applicable exercise and purchase prices, according to the filing.

The Company also disclosed that on October 22, 2026, it issued a press release announcing the reverse stock split, which is attached as Exhibit 99.1 to the Current Report. Equiniti, identified in the filing as the Company's transfer agent, is serving as the exchange agent for the reverse stock split. Stockholders holding shares through a broker, bank, or other nominee will generally have their positions adjusted automatically and will not be required to take any action, according to the filing.

What Was Disclosed

Envoy Medical filed an 8-K disclosing the completion of a 1-for-10 reverse stock split of its Class A common stock, effective October 26, 2026, following stockholder approval on October 12, 2026, and board authorization of the 1-for-10 ratio on the same date.